Ensaculin HCl | KA-672 | CAS#209969-60-8 | CAS#155773-59-4

MedKoo Cat#: 326921 | Name: Ensaculin HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ensaculin, also known as KA-672, is a NMDA antagonist and a 5HT1A agonist potentially for the treatment of Alzheimer's disease (AD). Ensaculin showed memory-enhancing effects in paradigms of passive and conditioned avoidance in both normal and artificially amnesic rodents. It exhibited neuroprotective activities in an NMDA toxicity model and neurotrophic effects in primary cultured rat brain cells. In receptor-binding studies, ensaculin was found to have high affinities to serotonergic 5-HT(1A) and 5-HT(7) receptors, adrenergic alpha(1), and dopaminergic D(2) and D(3) receptors.

Chemical Structure

Ensaculin HCl

CAS#209969-60-8 (HCl)

Theoretical Analysis

MedKoo Cat#: 326921

Name: Ensaculin HCl

CAS#: 209969-60-8 (HCl)

Chemical Formula: C26H33ClN2O5

Exact Mass: 488.2078

Molecular Weight: 489.01

Elemental Analysis: C, 63.86; H, 6.80; Cl, 7.25; N, 5.73; O, 16.36

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

155773-59-4 (free base) 209969-60-8 (HCl)

Synonym

KA 672; KA672; KA-672 HCl; Anseculin Hydrochloride; Ensaculin

IUPAC/Chemical Name

7-methoxy-6-(3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)-3,4-dimethyl-2H-chromen-2-one hydrochloride

InChi Key

XMONKHCPLIYQCY-UHFFFAOYSA-N

InChi Code

InChI=1S/C26H32N2O5.ClH/c1-18-19(2)26(29)33-23-17-24(31-4)25(16-20(18)23)32-15-7-10-27-11-13-28(14-12-27)21-8-5-6-9-22(21)30-3;/h5-6,8-9,16-17H,7,10-15H2,1-4H3;1H

SMILES Code

O=C1C(C)=C(C)C2=CC(OCCCN3CCN(C4=CC=CC=C4OC)CC3)=C(OC)C=C2O1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 155773-59-4(Ensaculin) 209969-60-8 (Ensaculin hydrochloride)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 489.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Knauber J, Müller WE. Anseculin improves passive avoidance learning of aged mice. Pharmacol Res. 2003 Mar;47(3):225-33. PubMed PMID: 12591018. 2: Hoerr R, Noeldner M. Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58. Review. PubMed PMID: 12177685. 3: Teismann P, Ferger B. Effects of ensaculin on dopamine metabolite levels and K(+)-induced glutamate release. Eur J Pharmacol. 2000 Jun 16;398(2):247-50. PubMed PMID: 10854836. 4: Teismann P, Ferger B. In vivo effects of the putative cognitive enhancer KA-672.HCl in comparison with 8-hydroxy-2-(di-N-propylamino) tetralin and haloperidol on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and 5-hydroxyindoleacetic acid levels in striatal and cortical brain regions. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Feb;24(2):337-48. PubMed PMID: 10800755. 5: Teismann P, Ferger B. Comparison of the novel drug Ensaculin with MK-801 on the reduction of hydroxyl radical production in rat striatum after local application of glutamate. Brain Res. 2000 Feb 28;857(1-2):165-71. PubMed PMID: 10700564. 6: Reisner E, Nöldner M, Rossner S, Chatterjee SS, Bigl V, Schliebs R. Acute effect of KA-672, a putative cognitive enhancer, on neurotransmitter receptor binding in mouse brain. Neurosci Lett. 1999 Oct 29;274(3):187-90. PubMed PMID: 10548421. 7: Hilgert M, Nöldner M, Chatterjee SS, Klein J. KA-672 inhibits rat brain acetylcholinesterase in vitro but not in vivo. Neurosci Lett. 1999 Mar 26;263(2-3):193-6. PubMed PMID: 10213168. 8: Lishko PV, Maximyuk OP, Chatterjee SS, Nöldner M, Krishtal OA. The putative cognitive enhancer KA-672.HCl is an uncompetitive voltage-dependent NMDA receptor antagonist. Neuroreport. 1998 Dec 21;9(18):4193-7. PubMed PMID: 9926872. 9: Winter JC, Helsley SE, Rabin RA. The discriminative stimulus effects of KA 672, a putative cognitive enhancer: evidence for a 5-HT1A component. Pharmacol Biochem Behav. 1998 Jul;60(3):703-7. PubMed PMID: 9678654. 10: Sourgens H, Hoerr R, Biber A, Steinbrede H, Derendorf H. KA 672-HCl, a neuronal activator against dementia: tolerability, safety, and preliminary pharmacokinetics after single and multiple oral doses in healthy male and female volunteers. J Clin Pharmacol. 1998 Apr;38(4):373-81. PubMed PMID: 9590466.